Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novocure Limited (NASDAQ: NVCR) SEC filings page on Stock Titan provides access to the company’s official disclosures as a registrant under U.S. securities laws. Novocure is incorporated in Jersey and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37565. These filings document material events, financial performance and regulatory updates related to its Tumor Treating Fields (TTFields) oncology business.
Among the key documents available are Form 8-K current reports, which Novocure uses to announce items such as quarterly financial results, clinical trial decisions and regulatory milestones. Recent 8-K filings reference press releases on net revenues, active patient counts on TTFields therapy, and the termination of the LUNAR-4 trial, as well as regulatory approvals like Japan’s Ministry of Health, Labour and Welfare decision on Optune Lua for certain NSCLC patients.
Investors and researchers can also use this page to monitor periodic reports such as annual and quarterly filings when available, which typically include consolidated financial statements, details on research, development and clinical study expenses, and discussions of sales, marketing and general and administrative costs. These documents provide structured insight into Novocure’s TTFields-based product portfolio, including Optune Gio and Optune Lua, and the company’s spending on clinical and regulatory programs in glioblastoma, non-small cell lung cancer, mesothelioma and pancreatic cancer.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand changes in revenue, operating expenses, cash position and key clinical or regulatory disclosures. Users can also review insider and management-related filings such as Forms 3, 4 and 5 when available, to track equity transactions by directors and officers.
With real-time updates from EDGAR and AI-assisted explanations, this page serves as a focused resource for analyzing Novocure’s regulatory record, financial condition and material events that shape its TTFields oncology platform.
NovoCure Ltd's Chief Human Resources Officer, Michal Nath Puri, reported equity compensation and a related tax sale. On March 3, 2026, he received 40,100 ordinary shares as restricted share units that vest over three years and 58,672 stock options vesting over four years. On March 4, 2026, he sold 1,100 ordinary shares at a weighted average price of $13.3054 in a mandated “sell to cover” transaction to satisfy tax withholding, and held 201,322 ordinary shares directly afterward.
NovoCure Ltd Executive Chairman William F. Doyle reported multiple equity compensation transactions on March 3, 2026. He received stock options for 258,445 shares and an additional option grant for 30,072 shares, which are scheduled to vest in equal parts over four years, subject to continued employment.
On the same date, he acquired 200,000 ordinary shares from restricted share units that vest over three years and 200,284 ordinary shares from performance-based restricted stock units that vested. He then sold 50,557 and 21,330 ordinary shares at weighted average prices of $12.7865 and $13.4288 to cover tax withholding obligations under a mandatory “sell to cover” provision, leaving 328,397 ordinary shares held directly.
Mukund Paravasthu reported sales of Common stock using Morgan Stanley Smith Barney LLC as broker. The filing lists four transactions dated 01/11/2026, 02/27/2026, 03/02/2026, and 03/04/2026 showing share amounts and aggregate proceeds for each sale.
The amounts reported are 2,133 shares for $30,608.55, 1,555 shares for $21,247.21, 408 shares for $5,505.14, and 5,377 shares for $71,543.14, all listed as Common stock on NASDAQ and described as securities to be sold under restricted stock vesting entries.
NVCR Form 144: proposed sale notice for restricted common stock.
The filing lists 6,412 restricted common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services with an execution date of 03/04/2026. The filing also shows prior sales by Uri Weinberg of 3,272 shares on 03/02/2026 and 7,461 shares on 02/27/2026.
Mukund Paravasthu filed a Form 144 reporting a proposed sale of 5,377 shares of common stock.
The filing lists prior sales in the past three months: 408 shares on 03/02/2026 and 1,555 shares on 02/27/2026. The securities are common stock intended for sale under Rule 144 on NASDAQ.
NVCR filed a Form 144 reporting a proposed sale of 5,607 restricted common shares through Morgan Stanley Smith Barney LLC dated 03/04/2026. The filing also lists recent dispositions: 7,232 shares sold on 03/02/2026 and 9,734 shares sold on 02/27/2026, each with associated dollar figures in the excerpt.
NovoCure Ltd Chief Medical and Innovation Officer Uri Weinberg reported a mix of share grants and mandated sales. On February 28, he acquired 12,992 ordinary shares at $0.00 per share from vesting of performance-based restricted stock units. Around these vestings, a total of 10,733 shares were sold in open-market transactions on February 27 and March 2 at weighted average prices of about $13.84 and $13.33 per share to cover tax withholding obligations under NovoCure’s equity plans, described as non-discretionary “sell to cover” trades. After these transactions, Weinberg directly owned 223,477 ordinary shares.
NovoCure Ltd’s Chief Human Resources Officer, Michal Nath Puri, reported an automatic sale of 1,441 Ordinary Shares. The shares were sold on February 27, 2026 in open-market trades at a weighted average price of about $13.66 per share, within a range of $13.45 to $13.97.
According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units, not a discretionary trade. After this sale, Puri directly held 162,322 Ordinary Shares of NovoCure.